Douglas W Ball

Associate Professor

1992 …2019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Douglas W Ball is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 1 Similar Profiles
Thyroid Neoplasms Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Neuroendocrine Tumors Medicine & Life Sciences
Small Cell Lung Carcinoma Medicine & Life Sciences
Mitogen-Activated Protein Kinase Kinases Medicine & Life Sciences
Lung Neoplasms Medicine & Life Sciences
Neoplasm DNA Medicine & Life Sciences
Pheochromocytoma Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1992 2019

A phase i trial of the VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced solid tumors and differentiated thyroid cancers

Kurzrock, R., Ball, D. W., Zahurak, M. L., Nelkin, B. D., Subbiah, V., Ahmed, S., O'Connor, A., Karunsena, E., Parkinson, R., Bishop, J. A., Ha, Y., Sharma, R., Gocke, C., Zinner, R., Rudek-Renaut, M., Sherman, S. I. & Azad, N., Sep 15 2019, In : Clinical Cancer Research. 25, 18, p. 5475-5484 10 p.

Research output: Contribution to journalArticle

Vascular Endothelial Growth Factor Receptor
Mitogen-Activated Protein Kinase Kinases
Thyroid Neoplasms
Protein-Tyrosine Kinases
Neoplasms

Genomic Profiling of Parathyroid Carcinoma Reveals Genomic Alterations Suggesting Benefit from Therapy

Kang, H., Pettinga, D., Schubert, A. D., Ladenson, P. W., Ball, D. W., Chung, J. H., Schrock, A. B., Madison, R., Frampton, G. M., Stephens, P. J., Ross, J. S., Miller, V. A. & Ali, S. M., Jan 1 2018, (Accepted/In press) In : Oncologist.

Research output: Contribution to journalArticle

Parathyroid Neoplasms
Neoplasms
Mutation
Tumor Burden
Multiple Endocrine Neoplasia Type 1

Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma

Schlumberger, M., Elisei, R., Müller, S., Schöffski, P., Brose, M., Shah, M., Licitra, L., Krajewska, J., Kreissl, M. C., Niederle, B., Cohen, E. E. W., Wirth, L., Ali, H., Clary, D. O., Yaron, Y., Mangeshkar, M., Ball, D. W., Nelkin, B. D. & Sherman, S., Jan 1 2017, In : Annals of Oncology. 28, 11, p. 2813-2819 7 p.

Research output: Contribution to journalArticle

Survival Analysis
Placebos
Survival
Confidence Intervals
Disease-Free Survival

A phase II trial of the multitargeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer

Schlumberger, M., Jarzab, B., Cabanillas, M. E., Robinson, B., Pacini, F., Ball, D. W., McCaffrey, J., Newbold, K., Allison, R., Martins, R. G., Licitra, L. F., Shah, M. H., Bodenner, D., Elisei, R., Burmeister, L., Funahashi, Y., Ren, M., O'Brien, J. P. & Sherman, S. I., Jan 1 2016, In : Clinical Cancer Research. 22, 1, p. 44-53 10 p.

Research output: Contribution to journalArticle

Protein-Tyrosine Kinases
Confidence Intervals
Disease-Free Survival
Angiopoietin-2
Neoplasms

Anaplastic thyroid carcinoma, version 2.2015

Haddad, R. I., Lydiatt, W. M., Ball, D. W., Busaidy, N. L., Byrd, D., Callender, G., Dickson, P., Duh, Q. Y., Ehya, H., Haymart, M., Hoh, C., Hunt, J. P., Iagaru, A., Kandeel, F., Kopp, P., Lamonica, D. M., McCaffrey, J. C., Moley, J. F., Parks, L., Raeburn, C. D. & 10 others, Ridge, J. A., Ringel, M. D., Scheri, R. P., Shah, J. P., Smallridge, R. C., Sturgeon, C., Wang, T. N., Wirth, L. J., Hoffmann, K. G. & Hughes, M., Sep 1 2015, In : JNCCN Journal of the National Comprehensive Cancer Network. 13, 9, p. 1140-1150 11 p.

Research output: Contribution to journalArticle

docetaxel
Thyroid Neoplasms
Practice Guidelines
Doxorubicin
Cisplatin